《Cell,4月2日,Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-04-05
  • Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

    Shibo Jiang

    Christopher Hillyer

    Lanying Du

    Open AccessPublished:April 02, 2020DOI:https://doi.org/10.1016/j.it.2020.03.007

    Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.

  • 原文来源:https://www.cell.com/trends/immunology/fulltext/S1471-4906(20)30057-0
相关报告
  • 《Nature,7月15日,Potently neutralizing and protective human antibodies against SARS-CoV-2》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-07-28
    • Potently neutralizing and protective human antibodies against SARS-CoV-2 Seth J. Zost, Pavlo Gilchuk, […]James E. Crowe Jr Nature (2020) Abstract The COVID-19 pandemic is a major threat to global health1 for which there are limited medical countermeasures2,3. Moreover, we currently lack a thorough understanding of mechanisms of humoral immunity4. From a larger panel of human monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein5, we identified several that exhibited potent neutralizing activity and fully blocked the receptor-binding domain of S (SRBD) from interacting with human ACE2 (hACE2). Competition-binding, structural, and functional studies allowed clustering of the mAbs into classes recognizing distinct epitopes on the SRBD as well as distinct conformational states of the S trimer. Potent neutralizing mAbs recognizing non-overlapping sites, COV2-2196 and COV2-2130, bound simultaneously to S and synergistically neutralized authentic SARS-CoV-2 virus. In two mouse models of SARS-CoV-2 infection, passive transfer of either COV2-2196 or COV2-2130 alone or a combination of both mAbs protected mice from weight loss and reduced viral burden and inflammation in the lung. In addition, passive transfer of each of two of the most potently ACE2 blocking mAbs (COV2-2196 or COV2-2381) as monotherapy protected rhesus macaques from SARS-CoV-2 infection. These results identify protective epitopes on SRBD and provide a structure-based framework for rational vaccine design and the selection of robust immunotherapeutics.
  • 《CELL,5月5日,Identification of human single-domain antibodies against SARS-CoV-2》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-05-05
    • Identification of human single-domain antibodies againstSARS-CoV-2 Yanling Wu,Cheng Li,Shuai Xia,Xiaolong Tian,Yu Kong,Zhi Wang,Chenjian Gu,Rong Zhang,Chao Tu,2 Youhua Xie,1 Zhenlin Yang,3 Lu Lu,1Shibo Jiang,Tianlei Ying1,4 5 * SUMMARY The worldwide spread of COVID-19 highlights the need for an efficient approach torapidly develop therapeutics and prophylactics against SARS-CoV-2. TheSARS-CoV-2 spike protein, containing the receptor-binding domain (RBD) and S1subunit involved in receptor engagement, is a potential therapeutic target. We describethe development of a phage-displayed single-domain antibody library by graftingnaïve complementarity-determining regions (CDRs) into framework regions of ahuman germline immunoglobulin heavy chain variable region (IGHV) allele. Panningthis library against SARS-CoV-2 RBD and S1 subunit identified fully humansingle-domain antibodies targeting five distinct epitopes on SARS-CoV-2 RBD withsubnanomolar to low nanomolar affinities. Some of these antibodies neutralizeSARS-CoV-2 by targeting a cryptic epitope located in the spike trimeric interfaCollectively, this work presents a versatile platform for rapid antibody isolation andidentifies promising therapeutic anti-SARS-CoV-2 antibodies as well as the diverseimmogneic profile of the spike protein